Gliclazide extended release - Beijing CoSci Med Tech
Latest Information Update: 10 Aug 2016
At a glance
- Originator Beijing CoSci Med-Tech
- Class Antihyperglycaemics; Sulfonylureas
- Mechanism of Action Insulinotropin agonists; Potassium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Diabetes mellitus
Most Recent Events
- 10 Aug 2016 Chemical structure information added
- 26 Jul 2016 Investigation in Diabetes mellitus in China (PO)